Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants

Katz, Arie, Udata, Chandrasekhar, Ott, Elyssa, Hickey, Lisa, Burczynski, Michael E., Burghart, Peter, Vesterqvist, Ole, Meng, Xu·2009·The Journal of Clinical Pharmacology

Abstract

Liver X‐receptor (LXR) agonists have been postulated to enhance reverse cholesterol transport (RCT), a process believed to shuttle cholesterol from the periphery back to the liver. Enhancing RCT via the upregulation of cholesterol transporters such as the adenosine triphosphate—binding cassettes ABCA1 and ABCG1 could therefore inhibit the progression of atherosclerosis. LXR‐623 is a synthetic ligand for LXRs α and β that has shown promise in animal models of atherosclerosis. The authors present results from a single ascending‐dose study of the safety, pharmacokinetics, and pharmacodynamics of LXR‐623 in healthy participants. LXR‐623 was absorbed rapidly with peak concentrations (C max) achieved at approximately 2 hours. The C max and area under the concentration‐time curve increased in a dose‐proportional manner. The mean terminal disposition half‐life was between 41 and 43 hours independently of dose. LXR activation resulted in a dose‐dependent increase in ABCA1 and ABCG1 expression. The effect of LXR‐623 concentration on ABCA1 and ABCG1 expression was further characterized via a population pharmacokinetic‐pharmacodynamic analysis, yielding EC 50 estimates of 526 ng/mL and 729 ng/mL, respectively. Central nervous system—related adverse events were observed at the 2 top doses tested. The pharmacodynamic effects described here are the first demonstration of “target engagement” by an LXR agonist in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0091270009335768

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 215

Metadata

Authors
Katz, A., Udata, C., Ott, E., Hickey, L., Burczynski, M. E., Burghart, P., Vesterqvist, O., & Meng, X.
Venue
The Journal of Clinical Pharmacology
Publisher
Wiley
Published
2009-06
Volume
49
Issue
6
Pages
643-649
ISSN
  • 0021-9754 (ISSN-L)
  • 0091-2700
  • 1552-4604
OpenAlex
W1963933860
Cited by
215
References
5
FWCI
11.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants. https://app.cochat.ai/papers/10.1177/0091270009335768
The paper
Katz, A., Udata, C., Ott, E., Hickey, L., Burczynski, M. E., Burghart, P., Vesterqvist, O., & Meng, X. (2009). Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270009335768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.